Loading organizations...
§ Private Profile · Shanghai, China
Private equity firm making growth equity investments and fund of funds in China, specializing in healthcare and TMT sectors.
Key people at CDBI Partners.
CDBI Partners is a Shanghai, China-based private equity firm that specializes in executing growth equity investments and managing fund of funds portfolios. The institution primarily directs its capital allocation strategies toward rapidly scaling domestic enterprises operating within the healthcare, technology, media, and telecommunications sectors. Operating with a highly concentrated corporate structure, the firm currently maintains a lean staff of exactly two dedicated team members to oversee its financial operations, portfolio management, and investment vehicles. By utilizing a dual-pronged business model, the organization generates returns through direct growth equity stakes and indirect investments across other specialized regional funds, navigating a competitive ecosystem that features major industry players like Tencent, Mindray, and ByteDance. To strategically capitalize on emerging market opportunities across the broader Asian financial landscape, the private equity organization was formally established by Founding Partner Qing Tan.
Key people at CDBI Partners.
CDBI Partners has 1 tracked investment across 1 company. The latest tracked deal is $20.0M Series A in Singlera Genomics in August 2016.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Aug 22, 2016 | Singlera Genomics | $20.0M Series A | FEI Chen | Green Pine Capital Partners |
CDBI Partners is a Shanghai-based private equity and venture capital firm specializing in growth equity and fund-of-funds investments in China, with a primary focus on Healthcare (including Biotech, HealthTech, Medical Devices) and Technology, Media & Telecommunications (TMT) sectors.[1][2] The firm has made 90 investments, achieved 12 portfolio exits (such as Aidite Technology's acquisition in June 2024), and manages 2 funds, contributing to China's startup ecosystem by backing high-growth companies in critical innovation areas like medical tech and digital transformation.[1] Its investment philosophy emphasizes scalable opportunities in these sectors, supporting ecosystem growth through capital infusion and strategic partnerships, as seen in co-investments with firms like Gaorong Capital and Legend Star.[1]
CDBI Partners operates from Room 1108, CITIC Pacific Plaza in Shanghai, China, with contact at +8621 62609156, but specific founding year and key partners are not detailed in available records.[1] The firm has evolved as a player in China's PE/VC landscape, focusing on growth-stage investments in healthcare and TMT, evidenced by its 90 investments and recent exits like Aidite Technology.[1] It has participated in notable funding rounds, such as angel investments in 2017-2018 and later backing for companies like SprintRay, highlighting its progression amid China's booming tech-health intersection.[1]
CDBI Partners rides China's healthcare-tech convergence trend, where aging demographics and digital innovation drive demand for Biotech, HealthTech, and Medical Devices amid post-pandemic recovery.[1][2] Timing aligns with government pushes for tech self-reliance and TMT expansion, positioning the firm to capitalize on market forces like rising VC inflows into Asia-Pacific innovation.[1] It influences the ecosystem by enabling exits (12 to date) and scaling startups, fostering a cycle of reinvestment in Shanghai's vibrant scene and bridging domestic growth with global co-investors.[1]
CDBI Partners is poised to expand in AI-health intersections and TMT amid China's 2025+ tech boom, potentially increasing exits and fund raises as portfolio matures. Trends like digital health scalability and cross-border syndicates will shape its path, evolving its influence from regional backer to key Asia-Pacific growth engine—building on its 90 investments to drive the next wave of Chinese unicorns.[1][2]
